B. Riley analyst Mayank Mamtani raised the firm’s price target on Checkpoint Therapeutics to $15 from $7 and keeps a Buy rating on the shares. The analyst adjusted the target following the 10:1 reverse split implemented this month and after the announcement of the $7.5M follow-on offering this week. He remains buyers of the stock going into the Biologics License Application filing for cosibelimab expected in January.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CKPT:
- Checkpoint Therapeutics announces $7.5M registered direct offering priced ATM
- Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biotech Alert: Searches spiking for these stocks today
- Checkpoint Therapeutics Announces Reverse Stock Split
- Checkpoint Therapeutics to effect 1-for-10 reverse stock split